Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients.
Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a…
Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an…
Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the…
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of…
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
